User menu

Efficacy and safety of subcutaneous golimumab in methotrexate-naïve patients with rheumatoid arthritis: 5-year results of the GO-BEFORE trial.

Bibliographic reference Emery, Paul ; Fleischmann, Roy M ; Strusberg, Ingrid ; Durez, Patrick ; Nash, Peter ; et. al. Efficacy and safety of subcutaneous golimumab in methotrexate-naïve patients with rheumatoid arthritis: 5-year results of the GO-BEFORE trial.. In: Arthritis Care & Research, (2015)
Permanent URL http://hdl.handle.net/2078.1/172485
  1. Emery Paul, Fleischmann Roy M., Moreland Larry W., Hsia Elizabeth C., Strusberg Ingrid, Durez Patrick, Nash Peter, Amante Eric Jason B., Churchill Melvin, Park Won, Pons-Estel Bernardo Antonio, Doyle Mittie K., Visvanathan Sudha, Xu Weichun, Rahman Mahboob U., Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis, 10.1002/art.24638
  2. Keystone E C, Genovese M C, Klareskog L, Hsia E C, Hall S T, Miranda P C, Pazdur J, Bae S-C, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman M U, Golimumab, a human antibody to tumour necrosis factor   given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study, 10.1136/ard.2008.099010
  3. Smolen Josef S, Kay Jonathan, Doyle Mittie K, Landewé Robert, Matteson Eric L, Wollenhaupt Jürgen, Gaylis Norman, Murphy Frederick T, Neal Jeffrey S, Zhou Yiying, Visvanathan Sudha, Hsia Elizabeth C, Rahman Mahboob U, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial, 10.1016/s0140-6736(09)60506-7
  4. Emery Paul, Fleischmann Roy M., Doyle Mittie K., Strusberg Ingrid, Durez Patrick, Nash Peter, Amante Eric, Churchill Melvin, Park Won, Pons-Estel Bernardo, Xu Weichun, Xu Stephen, Wu Zhong, Hsia Elizabeth C., Golimumab, a Human Anti-Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1-Year and 2-Year Clinical, Radiologic, and Physical Function Findings : Efficacy and Safety of Golimumab in MTX-Naive RA Patients, 10.1002/acr.22072
  5. Emery Paul, Fleischmann Roy, van der Heijde Désirée, Keystone Edward C., Genovese Mark C., Conaghan Philip G., Hsia Elizabeth C., Xu Weichun, Baratelle Anna, Beutler Anna, Rahman Mahboob U., The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy, 10.1002/art.30263
  6. Felson David T., Anderson Jennifer J., Boers Maarten, Bombardier Claire, Furst Daniel, Goldsmith Charles, Katz Linda M., Lightfoot Robert, Paulus Harold, Strand Vibeke, Tugwell Peter, Weinblatt Michael, James Williams H., Wolfe Frederick, Kieszak Stephanie, American college of rheumatology preliminary definition of improvement in rheumatoid arthritis, 10.1002/art.1780380602
  7. van Gestel A. M., Prevoo M. L. L., van't Hof M. A., van Rijswijk M. H., van de Putte L. B. A., van Riel P. L. C. M., Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, 10.1002/art.1780390105
  8. Smolen J. S., Breedveld F. C., Schiff M. H., Kalden J. R., Emery P., Eberl G., van Riel P. L., Tugwell P., A simplified disease activity index for rheumatoid arthritis for use in clinical practice, 10.1093/rheumatology/keg072
  9. Aletaha Daniel, Nell Valerie PK, Stamm Tanja, Uffmann Martin, Pflugbeil Stephan, Machold Klaus, Smolen Josef S, 10.1186/ar1740
  10. Fries James F., Spitz Patricia, Kraines R. Guy, Holman Halsted R., Measurement of patient outcome in arthritis, 10.1002/art.1780230202
  11. Lubeck Deborah P., Patient-Reported Outcomes and Their Role in the Assessment of Rheumatoid Arthritis : , 10.2165/00019053-200422001-00004
  12. Ware John E., Sherbourne Cathy Donald, The MOS 36-ltem Short-Form Health Survey (SF-36) : I. Conceptual Framework and Item Selection, 10.1097/00005650-199206000-00002
  13. Heijde Désirée M. F. M. Van Der, Leeuwen Miek A. Van, Riel Piet L. C. M. Van, Koster Anja M., Hof Martin A. Van't, Rijswijk Martin H. Van, Putte Levinus B. A. Van De, Biannual Radiographic Assessments of Hands and Feet in a Three-Year Prospective Followup of Patients with Early Rheumatoid Arthritis, 10.1002/art.1780350105
  14. Zhou Honghui, Jang Haishan, Fleischmann Roy M., Bouman-Thio Esther, Xu Zhenhua, Marini Joseph C., Pendley Charles, Jiao Qun, Shankar Gopi, Marciniak Stanley J., Cohen Stanley B., Rahman Mahboob U., Baker Daniel, Mascelli Mary Ann, Davis Hugh M., Everitt Daniel E., Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis, 10.1177/0091270006298188
  15. Van Riel PL van Gestel AM Scott DL. 2000
  16. Aletaha Daniel, Smolen Josef S., The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care, 10.1016/j.berh.2007.02.004
  17. Felson David T., Smolen Josef S., Wells George, Zhang Bin, van Tuyl Lilian H. D., Funovits Julia, Aletaha Daniel, Allaart Cornelia F., Bathon Joan, Bombardieri Stefano, Brooks Peter, Brown Andrew, Matucci-Cerinic Marco, Choi Hyon, Combe Bernard, de Wit Maarten, Dougados Maxime, Emery Paul, Furst Daniel, Gomez-Reino Juan, Hawker Gillian, Keystone Edward, Khanna Dinesh, Kirwan John, Kvien Tore K., Landewé Robert, Listing Joachim, Michaud Kaleb, Martin-Mola Emilio, Montie Pamela, Pincus Theodore, Richards Pamela, Siegel Jeffrey N., Simon Lee S., Sokka Tuulikki, Strand Vibeke, Tugwell Peter, Tyndall Alan, van der Heijde Desirée, Verstappen Suzan, White Barbara, Wolfe Frederick, Zink Angela, Boers Maarten, American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials, 10.1002/art.30129
  18. Genovese, J Rheumatol, 32, 1232 (2005)
  19. van der HEIJDE D., BREEDVELD F. C., KAVANAUGH A., KEYSTONE E. C., LANDEWE R., PATRA K., PANGAN A. L., Disease Activity, Physical Function, and Radiographic Progression After Longterm Therapy with Adalimumab Plus Methotrexate: 5-Year Results of PREMIER, 10.3899/jrheum.100208
  20. Moreland, J Rheumatol, 28, 1238 (2001)
  21. Burmester Gerd R, Matucci-Cerinic Marco, Mariette Xavier, Navarro-Blasco Francisco, Kary Sonja, Unnebrink Kristina, Kupper Hartmut, Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study, 10.1186/ar4452
  22. Galloway J. B., Hyrich K. L., Mercer L. K., Dixon W. G., Fu B., Ustianowski A. P., Watson K. D., Lunt M., Symmons D. P. M., , , Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly, 10.1093/rheumatology/keq242
  23. Hsia Elizabeth C., Cush John J., Matteson Eric L., Beutler Anna, Doyle Mittie K., Hsu Benjamin, Xu Stephen, Rahman Mahboob U., Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials, 10.1002/acr.21788
  24. Askling Johan, van Vollenhoven Ronald F., Granath Fredrik, Raaschou Pauline, Fored C. Michael, Baecklund Eva, Dackhammar Christina, Feltelius Nils, Cöster Lars, Geborek Pierre, Jacobsson Lennart T., Lindblad Staffan, Rantapää-Dahlqvist Solbritt, Saxne Tore, Klareskog Lars, Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment? : Anti-TNFα Therapy and Risk of Cancer, 10.1002/art.24941